Hematopoietic progenitor cell antigen CD34 and T-cell surface glycoprotein CD3 (CD34/CD3)

The target CD34+ hematopoietic progenitor cells / CD3+ T cells refers to a specific cellular composition used in allogeneic hematopoietic stem cell transplantation (HSCT) to treat hematologic malignancies and immune disorders. Hematopoietic progenitor cell antigen CD34 (UniProt P28906) is a sialomucin protein that serves as a marker for hematopoietic stem cells (HSCs), which are responsible for long-term marrow reconstitution (Miltenyi Biotec). T-cell surface glycoprotein CD3 (UniProt P07766) is a co-receptor complex involved in T-cell activation and the mediation of the graft-versus-leukemia (GVL) effect (NIH). However, donor CD3+ T cells are also the primary drivers of graft-versus-host disease (GvHD), a potentially fatal complication where donor cells attack the recipient's tissues (PubMed: 32853441). Therapeutic strategies targeting these populations involve graft engineering, such as the selective enrichment of CD34+ cells or the controlled depletion of CD3+ T cells using technologies like the CliniMACS system (Miltenyi Biotec). Precision cell therapy products like Orca-T (Orca Bio) further refine this by manipulating specific T-cell subsets to optimize the balance between preventing GvHD and maintaining anti-tumor immunity. This dual-target approach is essential for improving the safety and efficacy of transplants in patients with leukemia, lymphoma, and primary immunodeficiencies (StatPearls: NBK536964).

Other names

CD34+ hematopoietic progenitor cells / CD3+ T cellsCD34+ HSPCs and CD3+ T-lymphocytesCD34-selected/CD3-depleted graftHematopoietic stem cell and T-cell populations

The therapeutic approach involves the physical separation, enrichment, or depletion of specific cell populations from a donor graft. CD34+ selection ensures the presence of hematopoietic stem cells for engraftment, while CD3+ depletion or modulation reduces the number of alloreactive T-cells to prevent Graft-versus-Host Disease (GvHD) while attempting to preserve the Graft-versus-Leukemia (GVL) effect.